Add Yahoo as a preferred source to see more of our stories on Google. In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s ...

In the history of weird musical instrument interfaces, isomorphic keyboards are a favorite. These keyboards look like a grid of buttons, but when you play them, the relative shapes of chords are ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...

Isomorphic Labs, launched in 2021 with Google DeepMind, unveiled its newest joint AI offering AlphaFold 3, an AI model that was developed by Isomorphic Labs and Google DeepMind. According to ...

eSpeaks’ Corey Noles talks with Rob Israch, President of Tipalti, about what it means to lead with Global-First Finance and how companies can build scalable, compliant operations in an increasingly ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in the last 50 years. Demis Hassabis is at the helm of both Isomorphic and ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

Last year, DeepMind’s AlphaFold2 AI system made a “significant contribution to humanity’s understanding of biology.” Alphabet has now taken that advancement and created a new company called Isomorphic ...

The field of drug discovery has been supercharged by the capabilities of AI, which several companies have applied in various ways to turn an enormous practical problem into a tractable information ...

Editor’s note: Spike Brehm, the author of this post, is just one of the amazing hackers we’ve got speaking at DevBeat 2013, our first-ever developer conference taking place next week, Nov. 12-13 in ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.